{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:36Z","timestamp":1789726296189,"version":"4.0.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Orolingual angioedema (OA) secondary to administration of thrombolytic therapy is a rare, but serious, known adverse effect. Despite the lack of robust evidence for their use, C1 esterase inhibitors are recommended by guidelines for the treatment of refractory thrombolytic-associated OA. This report highlights the use of a C1 esterase inhibitor in a patient with tenecteplase-associated OA unresolved by antihistamine and corticosteroid therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 67-year-old white male with a history of hypertension managed with lisinopril presented to the emergency department with acute onset of slurred speech and left-sided hemiparesis. Following workup, an outside hospital\u2019s neurology stroke team suspected an acute infarct and determined the patient to be a candidate for tenecteplase. Approximately 1 hour after tenecteplase administration, the patient began complaining of dyspnea and mild oral angioedema. Immediate interventions for OA management included intravenous therapy with dexamethasone 10 mg, diphenhydramine 25 mg, and famotidine 20 mg. After an additional 30 minutes, the patient\u2019s OA symptoms continued to progress and a C1 esterase inhibitor (Berinert) was administered. Shortly after administration of the C1 esterase inhibitor, the patient\u2019s symptoms continued to worsen, ultimately leading to endotracheal intubation. Following intubation, symptom improvement was noted, and the patient was safely extubated after 30 hours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although rare, OA is a potentially life-threatening complication of tenecteplase therapy and requires prompt pharmacological intervention to optimize patient outcomes. Currently, no single agent or treatment algorithm exists that has shown significant efficacy or safety in the setting of thrombolytic-associated OA. Until data are available for C1 esterase inhibitors in this application, these inhibitors should only be considered if there is continued symptom progression after intravenous administration of corticosteroids and antihistamines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxad334","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T15:19:53Z","timestamp":1705677593000},"page":"e220-e225","source":"Crossref","is-referenced-by-count":10,"title":["Tenecteplase-associated orolingual angioedema: A case report and literature review"],"prefix":"10.1093","volume":"81","author":[{"given":"Jeffrey K","family":"Pitts","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Licking Memorial Hospital , Newark, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan M","family":"Burns","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Licking Memorial Hospital , Newark, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R","family":"Patellos","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Licking Memorial Hospital , Newark, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"issue":"10","key":"2024041915492745700_CIT0001","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11940-022-00733-4","article-title":"Tenecteplase or alteplase: what is the thrombolytic agent of the future","volume":"24","author":"Mahmood","year":"2022","journal-title":"Curr Treat Options Neurol"},{"issue":"10347","key":"2024041915492745700_CIT0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"issue":"10377","key":"2024041915492745700_CIT0003","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial","volume":"401","author":"Wang","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"2024041915492745700_CIT0004","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol"},{"issue":"17","key":"2024041915492745700_CIT0005","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","article-title":"Tenecteplase versus alteplase before thrombectomy for ischemic stroke","volume":"378","author":"Campbell","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2024041915492745700_CIT0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/23969873221150022","article-title":"European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke","volume":"8","author":"Alamowitch","year":"2023","journal-title":"Eur Stroke J"},{"issue":"11","key":"2024041915492745700_CIT0007","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1161\/STROKEAHA.120.029749","article-title":"Tenecteplase thrombolysis for acute ischemic stroke","volume":"51","author":"Warach","year":"2020","journal-title":"Stroke"},{"issue":"5","key":"2024041915492745700_CIT0008","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/STROKEAHA.122.042335","article-title":"Complications of intravenous tenecteplase versus alteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis","volume":"54","author":"Rose","year":"2023","journal-title":"Stroke"},{"key":"2024041915492745700_CIT0009","article-title":"Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS)","author":"Shi","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"15","key":"2024041915492745700_CIT0010","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2165\/00003088-200241150-00001","article-title":"Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction","volume":"41","author":"Tanswell","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"2024041915492745700_CIT0011","author":"Activase (alteplase)","year":"2015"},{"key":"2024041915492745700_CIT0012","author":"TNKase (tenecteplase)"},{"issue":"3","key":"2024041915492745700_CIT0013","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/STROKEAHA.120.030859","article-title":"Routine use of tenecteplase for thrombolysis in acute ischemic stroke","volume":"52","author":"Zhong","year":"2021","journal-title":"Stroke"},{"issue":"1","key":"2024041915492745700_CIT0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.07.045","article-title":"Orolingual angiodema associated with alteplase treatment of acute stroke: a reappraisal","volume":"24","author":"Correia","year":"2015","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"4","key":"2024041915492745700_CIT0015","first-page":"379","article-title":"Urticaria, angioedema, and type I hypersensitivity reactions associated with fibrinolytic agents","volume":"40","author":"Duangemee","year":"2022","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"10","key":"2024041915492745700_CIT0016","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00415-005-0789-9","article-title":"Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke","volume":"252","author":"Engelter","year":"2005","journal-title":"J Neurol"},{"issue":"3","key":"2024041915492745700_CIT0017","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000201558","article-title":"Raising awareness of orolingual angioedema as a complication of thrombolysis in acute stroke patients","volume":"27","author":"Ottomeyer","year":"2009","journal-title":"Cerebrovasc Dis"},{"issue":"9","key":"2024041915492745700_CIT0018","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1212\/01.WNL.0000058840.66596.1A","article-title":"Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke","volume":"60","author":"Hill","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"2024041915492745700_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10030518","article-title":"The role of the plasminogen activation system in angioedema: novel insights on the pathogenesis","volume":"10","author":"Napolitano","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"2024041915492745700_CIT0020","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/01.STR.0000017284.77838.87","article-title":"Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach","volume":"33","author":"Molinaro","year":"2002","journal-title":"Stroke"},{"issue":"1","key":"2024041915492745700_CIT0021","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13104-019-4335-8","article-title":"Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors","volume":"12","author":"Marceau","year":"2019","journal-title":"BMC Res Notes"},{"issue":"8","key":"2024041915492745700_CIT0022","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1398-9995.2007.01427.x","article-title":"Nonallergic angioedema: role of bradykinin","volume":"62","author":"Bas","year":"2007","journal-title":"Allergy"},{"issue":"3","key":"2024041915492745700_CIT0023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.annemergmed.2010.03.032","article-title":"Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series","volume":"56","author":"Bas","year":"2010","journal-title":"Ann Emerg Med"},{"issue":"2","key":"2024041915492745700_CIT0024","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/WOX.0b013e31821359a2","article-title":"Hereditary angioedema caused by C1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies","volume":"4","author":"Gower","year":"2011","journal-title":"World Allergy Organ J"},{"issue":"12","key":"2024041915492745700_CIT0025","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"2024041915492745700_CIT0026","doi-asserted-by":"crossref","first-page":"292.e5","DOI":"10.1016\/j.ajem.2020.10.029","article-title":"Tranexamic acid for ACE inhibitor induced angioedema","volume":"43","author":"Wang","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"1","key":"2024041915492745700_CIT0027","first-page":"e972","article-title":"When nothing else works: fresh frozen plasma in the treatment of progressive, refractory angiotensin-converting enzyme inhibitor-induced angioedema","volume":"9","author":"Chaaya","year":"2017","journal-title":"Cureus"},{"issue":"1","key":"2024041915492745700_CIT0028","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12245-022-00408-6","article-title":"Bradykinin-induced angioedema in the emergency department","volume":"15","author":"H\u00e9bert","year":"2022","journal-title":"Int J Emerg Med"},{"issue":"10","key":"2024041915492745700_CIT0029","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1161\/STROKEAHA.122.040052","article-title":"Bradykinin-mediated angioedema following tenecteplase administration in an acute ischemic stroke","volume":"53","author":"Lapostolle","year":"2022","journal-title":"Stroke"},{"key":"2024041915492745700_CIT0030","volume-title":"International Reporting of Adverse Drug Reactions. CIOMS Working Group Report","author":"Council for International Organisations of Medical Sciences","year":"1987"},{"issue":"3","key":"2024041915492745700_CIT0031","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/1941875211408731","article-title":"Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies","volume":"1","author":"Miller","year":"2011","journal-title":"Neurohospitalist"},{"issue":"6","key":"2024041915492745700_CIT0032","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/MJT.0b013e3182799083","article-title":"Angioedema from recombinant TPA administration: case report and pathophysiology review","volume":"20","author":"Foster-Goldman","year":"2013","journal-title":"Am J Ther"},{"issue":"1","key":"2024041915492745700_CIT0033","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jemermed.2013.02.004","article-title":"Orolingual angioedema with alteplase administration for treatment of acute ischemic stroke","volume":"45","author":"Gorski","year":"2013","journal-title":"J Emerg Med"},{"issue":"5","key":"2024041915492745700_CIT0034","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jemermed.2013.03.045","article-title":"Angioedema: etiology, pathophysiology, current and emerging therapies","volume":"45","author":"Lewis","year":"2013","journal-title":"J Emerg Med."},{"issue":"10","key":"2024041915492745700_CIT0035","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/ene.12472","article-title":"Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use","volume":"21","author":"Lin","year":"2014","journal-title":"Eur J Neurol"},{"issue":"3","key":"2024041915492745700_CIT0036","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1941874415587680","article-title":"Management of postthrombolysis hemorrhagic and orolingual angioedema complications","volume":"5","author":"O\u2019Carroll","year":"2015","journal-title":"Neurohospitalist"},{"issue":"7","key":"2024041915492745700_CIT0037","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1161\/STROKEAHA.116.013334","article-title":"Orolingual angioedema during or after thrombolysis for cerebral ischemia","volume":"47","author":"Myslimi","year":"2016","journal-title":"Stroke"},{"issue":"3","key":"2024041915492745700_CIT0038","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.annemergmed.2016.02.019","article-title":"A novel approach to the treatment of orolingual angioedema after tissue plasminogen activator administration","volume":"68","author":"Pahs","year":"2016","journal-title":"Ann Emerg Med"},{"key":"2024041915492745700_CIT0039","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fmed.2020.00358","article-title":"Measurement of bradykinin formation and degradation in blood plasma: relevance for acquired angioedema associated with angiotensin converting enzyme inhibition and for hereditary angioedema due to factor XII or plasminogen gene variants","volume":"7","author":"Marceau","year":"2020","journal-title":"Front Med"},{"issue":"9","key":"2024041915492745700_CIT0040","first-page":"1","article-title":"Tranexamic acid for the emergency treatment of angiotensin-converting enzyme inhibitor-induced angioedema","volume":"13","author":"Hasara","year":"2021","journal-title":"Cureus"},{"issue":"5","key":"2024041915492745700_CIT0041","first-page":"369.e1","article-title":"Bradykinin-mediated angioedema related to alteplase successfully treated by frozen fresh plasma (FFP) in Saudi Arabia: a first case report and literature review","volume":"12","author":"Narjes","year":"2021","journal-title":"J Neurol Neurosci"},{"key":"2024041915492745700_CIT0042","first-page":"407","article-title":"Recombinant human C1 esterase inhibitor in the management of hereditary angioedema. Clin Drug Ivestig","author":"Riedl","year":"2015"},{"issue":"2","key":"2024041915492745700_CIT0043","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ccr3.171","article-title":"Angiotensin-converting enzyme inhibitors\u2013induced angioedema treated by C1 esterase inhibitor concentrate (Berinert): about one case and review of the therapeutic arsenal","volume":"3","author":"Lipski","year":"2015","journal-title":"Clin Case Rep"},{"issue":"3","key":"2024041915492745700_CIT0044","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11739-015-1205-9","article-title":"Treatment of ACEI-related angioedema with icatibant: a case series","volume":"10","author":"Bova","year":"2015","journal-title":"Intern Emerg Med"},{"issue":"6","key":"2024041915492745700_CIT0045","doi-asserted-by":"crossref","first-page":"1125.e1","DOI":"10.1016\/j.ajem.2018.03.018","article-title":"Icatibant for the treatment of orolingual angioedema following the administration of tissue plasminogen activator","volume":"36","author":"Brown","year":"2018","journal-title":"Am J Emerg Med"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxad334\/56554424\/zxad334.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/9\/e220\/57241354\/zxad334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/9\/e220\/57241354\/zxad334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T12:17:22Z","timestamp":1713529042000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/9\/e220\/7589143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,1,25]]},"published-print":{"date-parts":[[2024,4,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxad334","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,1,25]]}}}